Sartorius Stedim Biotech (SDMHF) Stock Price, News & Analysis

Company Overview

Sartorius Stedim Biotech S.A. is a France-based provider of technologies and services used by the biopharmaceutical industry. The company supports the development and manufacture of biologic medicines, including vaccines, therapeutic proteins, and other advanced biological products.

Its portfolio includes single-use bioprocessing equipment and consumables, bioreactors and fermentation systems, filtration and purification technologies, fluid-management products, cell-culture solutions, and laboratory instruments. Sartorius Stedim Biotech also provides process-development, engineering, validation, and other services intended to help customers scale biopharmaceutical production from research through commercial manufacturing.

The company serves pharmaceutical and biotechnology customers internationally through operations and sales networks across Europe, North America, Asia, and other major biopharmaceutical markets. Sartorius Stedim Biotech was formed through the combination of Sartorius’ biotechnology activities and Stedim Biosystems and is majority-owned by German life-science technology group Sartorius AG.

Key Stats

• Today's Range: $242.02 to $242.02
• 50-Day Range: $202.00 to $245.89
• 52-Week Range: $178.30 to $264.30
• Volume: N/A
• Average Volume: 2,579 shs
• Market Capitalization: N/A
• P/E Ratio: 56.15
• Dividend Yield: 0.50%
• Price Target: N/A
• Consensus Rating: Moderate Buy

Sartorius Stedim Biotech Stock Analysis - MarketRank™

Sartorius Stedim Biotech scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Sartorius Stedim Biotech has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Sartorius Stedim Biotech has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Sartorius Stedim Biotech is 56.15, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.84.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sartorius Stedim Biotech is 56.15, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 177.31.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Sartorius Stedim Biotech has a short interest ratio ("days to cover") of 2.92, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sartorius Stedim Biotech has recently increased by 35.15%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

Sartorius Stedim Biotech has a dividend yield of 0.84%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Sartorius Stedim Biotech does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Sartorius Stedim Biotech is 27.84%. This payout ratio is at a healthy, sustainable level, below 75%.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Sartorius Stedim Biotech this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sartorius Stedim Biotech insiders have not sold or bought any company stock.

Percentage Held by Institutions

9.21% of the stock of Sartorius Stedim Biotech is held by institutions.

Company Calendar

• Today: 10/16/2026
• Next Earnings (Estimated): 10/22/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:SDMHF
• CIK: 1794363
• Web: www.sartorius.com
• Phone: (344) 284-5600
• Fax: N/A
• Employees: 10,382
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 56.15
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A